1-3 of 3
Lisa Davis, PharmD
Close
Sort by
Journal Articles

Phase II/1b Trial of Ibrutinib Plus Prednisone and Rituximab Induction Followed By Venetoclax Plus Ibrutinib Maintenance in Newly Diagnosed High-Risk Chronic Lymphocytic Leukemia

Soyoung Park, MD, Lisa Davis, PharmD, Paul Hsu, PhD, Daniel Persky, MD, Daruka Mahadevan, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5351.
https://doi.org/10.1182/blood.V130.Suppl_1.5351.5351
Published: 2017
Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Dan T. Vogl, MD, MSCE, Edward A. Stadtmauer, MD, James Bradner, MD, Lisa Davis, PharmD, Thomas M. Paul, Emma C. Scott, MD, Charles W. Nichols, MD, David L. Porter, MD, Martin Carroll, MD, Janeen Kaplan, Gayle Mallon, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Ravi K. Amaravadi, MD
Journal: Blood
Blood (2011) 118 (21): 1869.
https://doi.org/10.1182/blood.V118.21.1869.1869
Published: 2011
Journal Articles

Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma

Dan T. Vogl, MD, MSCE, Eric Stoopler, DMD, Lisa Davis, PharmD, Thomas M. Paul, German Salazar, DDS, Maria Raguza-Lopez, David L. Porter, MD, Selina M. Luger, MD, Edward A. Stadtmauer, MD
Journal: Blood
Blood (2010) 116 (21): 1349.
https://doi.org/10.1182/blood.V116.21.1349.1349
Published: 2010